



SCIENTIFIC DIVISION

41st MEETING

Antalya, TR (2008 4 11, 12 & 14)

MINUTES (*second draft*)

Members:	Abbr.	Term and Time of Office
Mauro PANTEGHINI (IT) (Chair)	MP	1 st 2006 01 - 2008 12
Ian YOUNG (UK) (Vice-Chair)	IY	1 st 2006 01 - 2008 12
Howard MORRIS (AU) (Secretary)	HM	2 nd 2006 01 - 2008 12
Philippe GILLERY (FR)	PG	1 st 2006 01 - 2008 12
Lothar SIEKMANN (DE)	LS	1 st 2006 01 - 2008 12
Ulf-Hakan STENMAN (FI)	UHS	2 nd 2006 01 - 2008 12
George BROTEA (US) (Corporate Representative)	GB	1 st 2007 01 - 2009 12
David BUNK (NIST Representative)	DB	Consultant
Heinz SCHIMMEL (IRMM Representative)	HS	Consultant
Jean-Claude FOREST (JCTLM Representative)	JCF	Consultant
Mathias MÜLLER (EB Liaison)	MMM	

Executive Summary - Scientific Division 41st Meeting, Antalya, Turkey April 11,12 & 14, 2008.

Present: Mauro Panteghini (Chair), Ian Young (Vice-Chair), Howard Morris (Secretary), Philippe Gillery, Lothar Siekmann, Ulf-Hakan Stenman and George Brotea (Corporate Representative), Heinz Schimmel (IRMM Consultant) and Jean-Claude Forest (JCTLM Consultant) with Ms Paola Bramati (IFCC Office) were in attendance.

6.2 CLSI: A new agreement has been reached between the CLSI and IFCC outlining the procedures and individual responsibilities for undertaking joint projects.

6.22.1 JCTLM: JCTLM WG1 met in October 2007 and decided on Cycle IV nominations for reference materials and methods and WG2 met to decide on Cycle II nominations for reference networks.

6.22.2 JCGM: The final version of VIM 3rd edition has been published on the VIM web site and is awaiting publication on web sites of affiliated organizations including the IFCC.

6.31 INSTITUTE FOR REFERENCE MATERIALS AND MEASUREMENTS (IRMM)

Projects are progressing to prepare Certified Reference Materials in collaboration with a number of SD Committees and Working Groups including 2nd Batch CRM470 (ERM DA470), AST reference material, HbA2, myoglobin and cystatin C.

8.2 MAIN ACTIVITIES OF COMMITTEES

8.2.6 C-NPU: A manuscript on the reporting of the clinical analysis of urinary calculi has been published.

8.2.11 C-MD: Networks of IFCC 7 Expert Molecular Diagnostics Centres and 4 Member Laboratories have been enrolled.

8.2.13 C-PP: The protocol for transferring values from ERM-DA470 to commercial protein assay calibrators is in the final stages of preparation.

8.2.19 C-SMCD: A scientific letter reporting cross-reactivity of B-type Natriuretic Peptide assays has been published and two further manuscripts on Natriuretic Peptides are in preparation.

8.2.21 C-RSE: The certification process of the AST Reference Material, in cooperation with IRMM, continues with 10 laboratories participating.

8.2.22 C-POCT: Work is underway to prepare a database on potential interferents in POCT.

8.2.23 C-TLM: Reporting of Desirable Limits of Agreement to laboratories participating in the RELA ring trials has commenced.

8.2.24 C-RIDL: A manuscript describing a systematic review of creatinine reference intervals including data for pediatric age-adjusted reference intervals has been published.

8.3 MAIN ACTIVITIES OF WORKING GROUPS

8.3.3 WG-SEB: Priorities are currently being reviewed.

8.3.8 WG-A: The preparation of the new SP3-08 apo B reference material has been completed and is available for distribution.

8.3.16 WG-SHCG: Collaboration with the NIBSC/WHO to establish the 5th IS utilising purified intact HCG prepared by the WG is continuing.

8.3.19 WG-HbA1c: The minutes of a meeting held with IVD manufacturers have been published and a document providing advice on the implementation of the Consensus Document to the profession, clinicians and manufacturers is in preparation.

8.3.33 WG-STFT: A definition of the measurand for free thyroxine and a proposal for a candidate reference measurement procedure have been published.

8.3.35 WG-HbA2: Primary reference materials for HbA0 and HbA2 have been prepared and batches of candidate secondary reference material are in preparation.

8.3.36 WG-CDT: The preparation of a candidate primary reference material has been completed.

8.3.37 WG-SCC: A candidate secondary reference material has been aliquotted and the certification process is underway.

8.3.38 WG-GFRA: A number of companies will introduce new enzymatic assays by the end of 2008.

8.3.39 WG-SAU: A meeting was held, which agreed on a number of recommendations for the assay of albumin in urine and a manuscript is in preparation.

8.3.40 WG-PAPPA: A new reference preparation is required and a project for its preparation has commenced.

8.3.41 WG-GH: Preparatory work to assist with the reporting of GH results in mass units of GH IS 98/574 is underway.

8.3.42 WG-SIA: The performance of clinical insulin assays has been assessed by comparing results with those from an ID-LC/tandem MS assay calibrated with recombinant insulin and the results have been published.

8.3.43 WG-TnI: Fundamental studies of the interaction between cTnI antigen and 6 commercially available monoclonal antibodies are underway.

8.8 PROJECT PROPOSALS:

Proposals for two new projects in the field of steroid hormone assays are under consideration.

8.19 MEETINGS

8.19.41 - The 42nd SD meeting will take place in Fortaleza, Brazil 27th and 28th September, 2008.

MP's report on the SD activities to the GC (13 April), was very well received.